Photo taken from Jose Fernando Moura/Twitter
Oct 21, 2023, 19:37
Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.
Jose Fernando Moura, Oncologist and Principal Investigator in Solid Tumors at Real Hospital Portuguese and IMIP, shared on X/Twitter from ESMO23:
“One more for the team! Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line similar activity.”
Source: Jose Fernando Moura/Twitter.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08